Max S Wicha, MD

 Max Wicha, MD
Professor
Email:
[email protected]
Available to mentor
Max S Wicha, MD
Max Wicha, MD
Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • Qualifications
    • Biology Degree
      State University of NY at Stony Brook, United States
      1966 - 1970

    Center Memberships
    • Center Member
      Rogel Cancer Center
    • Center Member
      Taubman Institute
    • Center Member
      Center for Computational Medicine and Bioinformatics
    • Center Member
      MM-PKUHSC Joint Institute
    • Center Member
      Biointerfaces Institute
    • Center Member
      Center for Cell Plasticity and Organ Design
    • Center Member
      Global REACH

    Research Overview

    Mammary cell biology
    * Regulation of mammary growth, differentiation and apoptosis
    * Stem cells in normal mammary development and breast cancer
    * Cancer stem cell therapeutics

    Recent Publications

     See All Publications
    • Journal Article
      BET Protein Degrader ZBC260 Induces Tumor Vascular Reprogramming Through Endothelial Cell Remodeling
      Sharma D, Hager CG, Wicha MS, Burness M. Breast Cancer (Dove Med Press), 2026 Aug 25; 18: DOI:10.2147/BCTT.S626513
    • Journal Article
      Targeting bromodomain and extra-terminal proteins reprograms macrophages and inhibit breast cancer progression
      Hager C, Sharma D, Bushnell GG, Kalman AP, Shapiro GF, Xendzova KA, Walenjus L, Hutchens CM, Wicha MS, Burness M. Frontiers in Immunology, 2026 Aug 24; 17: DOI:10.3389/fimmu.2026.1738705
    • Journal Article
      CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer
      Gurrea-Rubio M, Sloan S, Chada A, Amarista CI, Maeda K, Campbell PL, Tsou PS, Cooney LA, Wicha MS, Fox DA. Biomolecules, 2026 Aug 17; 16 (8): DOI:10.3390/biom16081202
      PMID: 42650869
    • Preprint
      S100A9-Dependent CXCR2hi Neutrophils Mediate Systemic Immune Suppression and Checkpoint Resistance in Metastatic TNBC
      Alkan FK, Caglayan AB, Alkan HK, Lee E, Piranlioglu R, Jones C, Alimadadi M, Benson E, Arnold A, Gramer AL, Vogl T, Dyson G, Chadli A, Guzel M, Kasimir-Bauer S, Assad H, Boerner J, Al-Achkar M, Azmi AS, Neamati N, Ozturk G, Bollag R, Hedrick CC, Wicha MS, Shi H, Korkaya H. 2026 Jun 14; bioRxiv, DOI:10.64898/2026.06.09.731132
    • Journal Article
      Author Correction: Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology (Nature Immunology, (2021), 22, 11, (1440-1451), 10.1038/s41590-021-01048-3)
      Fujiwara H, Seike K, Brooks MD, Mathew AV, Kovalenko I, Pal A, Lee HJ, Peltier D, Kim S, Liu C, Oravecz-Wilson K, Li L, Sun Y, Byun J, Maeda Y, Wicha MS, Saunders TL, Rehemtulla A, Lyssiotis CA, Pennathur S, Reddy P. Nature Immunology, 2026 May 1; 27 (5): 1083 DOI:10.1038/s41590-026-02504-8
      PMID: 41876720
    • Journal Article
      Abstract 184: TNF-alpha plays pleiotropic role in innate immune activation and blood-brain barrier disruption driving brain metastasis.
      Celiker N, Alkan FK, Alkan HK, Caglayan A, Lawal A, Al Achkar M, Max WS, Korkaya H. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 184 - 184. DOI:10.1158/1538-7445.am2026-184
    • Journal Article
      Abstract 2375: Stress-responsive immune microenvironment in triple-negative breast cancer among African American women
      Lawal AM, Alkan FK, Alkan HK, Caglayan AB, Celiker N, Temby B, WICHA M, Al Achkar M, Purrington K, Korkaya H. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 2375 - 2375. DOI:10.1158/1538-7445.am2026-2375
    • Journal Article
      Abstract 3431: Neutrophil-like monocytes (NeuMos) with high levels of CXCL2 expression orchestrate systemic granulopoiesis and drive immunotherapy resistance in TNBC
      Alkan F, Alkan HK, Caglayan A, Caglayan A, Lawal A, Celiker N, Shi H, Vogl T, Neamati N, Max W, Korkaya H. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 3431 - 3431. DOI:10.1158/1538-7445.am2026-3431

    Featured News & Stories
    News Release

    Max Wicha set to retire after 46 years

    After 46 years of service, Max S. Wicha, MD, founding director of the University of Michigan Rogel Cancer Center, will retire from the University of Michigan and move to emeritus status.
         Max Wicha, M.D. and Sunitha Nagrath, Ph.D. Photo credit: Leisa Thompson
    Illuminate

    Nurturing High-Risk, High-Reward Ideas

    The Forbes Institute fosters cross-disciplinary collaboration, encouraging partnerships among faculty from various disciplines across the University of Michigan campus. Learn more about their research into tumor dormancy.